
CLOV Stock Forecast & Price Target
CLOV Analyst Ratings
Bulls say
Clover Health Investments is positioned to see strong growth in its core markets, with a large and growing membership base and high retention rates. This, combined with the utilization of its proprietary technology platform, Clover Assistant, has the potential to drive improved unit economics and profitability in the coming years. While there are potential headwinds in 2027, including a return to being paid as a 3.5-star plan and flat CMS rates, Clover's strong performance and track record of profitability make us optimistic about its future prospects. Our analysis suggests that the stock is currently undervalued and we maintain a BUY rating with a revised price target of $3.20.
Bears say
Clover Health Investments is facing multiple headwinds in the coming years, including a potential decrease in CMS MA advance rates and a shift to being paid as a 3.5-star plan. Despite management's focus on technology-driven improvements and cost containment, it is uncertain if the company can continue to profitably absorb a large new member cohort in 2026. However, strong retention rates in geographies with high Clover Assistant adoption could bode well for the company's financial performance. Additionally, potential regulatory changes to Medicare Advantage and Direct Contracting could negatively impact sentiment and profitability.
This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.
CLOV Analyst Forecast & Price Prediction
Start investing in CLOV
Order type
Buy in
Order amount
Est. shares
0 shares